(Q33639335)

English

A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1 reference

based on heuristic

inferred from title

author name string

M Thomas

1

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

P Sadjadian

2

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

J Kollmeier

3

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

J Lowe

4

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

P Mattson

5

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

J R Trout

6

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

M Gargano

7

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

M L Patchen

8

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

R Walsh

9

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

M Beliveau

10

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

J F Marier

11

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

N Bose

12

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

K Gorden

13

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

F Schneller

14

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

publication date

16 March 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

35

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

345-358

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

copyright license

Creative Commons Attribution 4.0 International

16 March 2017

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418307

21 June 2018

Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3-1,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418307

21 June 2018

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418307

21 June 2018

Binding of Soluble Yeast β-Glucan to Human Neutrophils and Monocytes is Complement-Dependent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418307

21 June 2018

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418307

21 June 2018

Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived β-glucans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418307

21 June 2018

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418307

21 June 2018

Effect of yeast-derived beta-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418307

21 June 2018

Yeast-derived beta-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418307

21 June 2018

Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418307

21 June 2018

Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418307

21 June 2018

The use of mushroom glucans and proteoglycans in cancer treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418307

21 June 2018

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0450-3

21 January 2018

Optimal flexible designs in phase II clinical trials.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0450-3

21 January 2018

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0450-3

21 January 2018

Identifiers

10.1007/S10637-017-0450-3

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33639335&oldid=2195600255"